A Comprehensive Review of Strategies for Improving Malaria Vaccine Implementation and Update

References

[1] World Health Organization. World Malaria Report 2023. Geneva: World Health Organization; 2023.

[2] Centres for Disease Control and Prevention (CDC). Global Malaria Prevention and Control Operations Manual. Atlanta: CDC; 2025.

[3] World Health Organization. Consolidated guidelines for malaria control and eradication: Strategic integration of seasonal vaccines. Geneva: World Health Organization; 2026.

[4] PATH Malaria Vaccine Initiative. Malaria vaccines: RTS,S and R21 Product Info Fact Sheet. Washington, DC: PATH; 2024.

[5] Nature Index. Malaria Vaccine Acceptance and Implementation Strategies. London: Springer Nature; 2024.

[6] African Union. Africa Health Strategy 2016-2030: Sustaining universal health coverage through immunization networks. Addis Ababa: African Union Commission; 2024.

[7] Global Fund to Fight AIDS, Tuberculosis and Malaria. Strategic investments in malaria elimination: Integrating vector control and vaccines. Geneva: The Global Fund; 2025.

[8] World Health Assembly. Accelerating progress toward global malaria targets: Operational mandates for national immunization systems. Geneva: WHA Secretariat; 2025.

[9] Journal of Public Health Policy. Bridging the policy-practice gap in sub-Saharan vaccine rollouts. J Public Health Policy. 2024; 45(2):189-201.

[10] World Health Organization. Guidance on the operational deployment of malaria vaccines (RTS,S and R21). Geneva: World Health Organization; 2024.

[11] Gavi, the Vaccine Alliance. Malaria Vaccine Implementation Support Framework: Lessons from the 2024–2025 African Rollouts. Geneva: Gavi Alliance; 2025.

[12] Health Policy and Planning. Registry bottlenecks in multi-dose pediatric immunization campaigns. Health Policy Plan. 2025; 40(1):78-89.

[13] African Journal of Public Health. Digital innovations in immunization: Overcoming the multi-dose dropout tracker challenge in rural health districts. Afr J Public Health. 2024; 18(3):142-151.

[14] Vaccine Acceptance Research Network (VARN). Behavioural drivers of multi-dose vaccine compliance in endemic regions. London: Sabin Vaccine Institute; 2024.

[15] Social Science & Medicine. Trust networks and maternal care: Harnessing community leadership for new vaccine introductions. Soc Sci Med. 2025; 310:115-126.

[16] World Health Organization. Malaria vaccine allocation framework: Managing supply constraints and optimizing health impact. Geneva: World Health Organization; 2024.

[17] Serum Institute of India. Scaling global immunization: R21/Matrix-M production capacity and delivery milestones. Pune: SII Media; 2025.

[18] Health Economics. Comparative cost-effectiveness analyses of novel biological interventions against P. falciparum. Health Econ. 2024; 33(8):1102-1115.

[19] Gavi, the Vaccine Alliance. Dual-vaccine market dynamics: Operational challenges in co-deploying RTS,S and R21 in sub-Saharan Africa. Geneva: Gavi Alliance; 2025.

[20] Intergovernmental Panel on Climate Change (IPCC). Health, wellbeing, and the changing structure of infectious disease vectors. Cambridge: Cambridge University Press; 2026.

[21] Gavi, the Vaccine Alliance. The co-financing challenge: Sustaining immunization programs through domestic resource mobilization. Geneva: Gavi Alliance; 2025.

[22] World Bank. Fiscal space for health in sub-Saharan Africa: Navigating donor transitions and macroeconomic shocks. Washington, DC: World Bank Group; 2024.

[23] Lancet Infectious Diseases. Immunization in fragile and conflict-affected settings: Lessons from the frontline. Lancet Infect Dis. 2025; 25(4):412-421.

[24] UNICEF. Reaching the unreached: Strategies for deploying the malaria vaccine to displaced populations and zero-dose children. New York: UNICEF; 2024.

[25] World Health Organization. Technical consultation on the structural threats of drug and diagnostic resistance in African malaria vectors. Geneva: World Health Organization; 2025.

[26] American Journal of Tropical Medicine and Hygiene. Long-term monitoring of R21/Matrix-M and RTS, S/AS01 efficacy profiles in real-world deployment. Am J Trop Med Hyg. 2026; 114(2):304-315.

@article{1718998,
      author = {Okoro Samuel Chukwu, Esular Nnenna Onu, Lovette Onyinye Nomeh, Stella Ajachukwu Uma, Veronica Felicitia Nwode; Eze Emmanuel Eze},
      title = {A Comprehensive Review of Strategies for Improving Malaria Vaccine Implementation and Update},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {9},
      number = {12},
      pages = {2413-2417},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1718998.pdf},
      abstract = {Malaria remains a critical public health threat in sub-Saharan Africa, disproportionately causing mortality in children under five years of age. The authorization and rollout of the RTS,S/AS01 and R21/Matrix-M vaccines have transformed global elimination strategies from passive vector management to active immunization. However, transitioning these biological innovations from controlled clinical environments into broad programmatic rollouts poses intricate operational, financial, and sociocultural challenges. This comprehensive review examines the critical intersection of health policy and grassroots execution. It systematically assesses supply-side vulnerabilities, including severe cold-chain infrastructure deficits in rural health systems and the tracking complexities associated with a strict four-dose schedule, alongside demand-side behavioural drivers like public vaccine hesitancy and the risk of diminished reliance on insecticide-treated nets. The analysis reveals that while the introduction of the mass-produced R21 variant effectively satisfies historical global supply constraints, local health ministries lack actionable, cost-effective frameworks to co-deploy dual-vaccine brands simultaneously. Furthermore, current literature frequently overlooks critical systemic threats, such as long-term domestic co-financing deficits, vaccine distribution networks within active conflict zones, and shifting geographical vector patterns accelerated by climate change. This review emphasizes that malaria vaccines cannot operate in structural isolation. Achieving sustainable reductions in childhood mortality requires the seamless integration of multi-dose immunization systems with existing primary healthcare services, vector controls, and robust localized communication networks. Public health authorities must urgently expand adaptive contingency plans to counter local economic, political, and biological resistance factors to realize the full life-saving potential of this dual-vaccine era.},
      keywords = {Malaria, Immunization, Vaccine Implementation, Sub-Saharan Africa, RTS, S/AS01, R21/Matrix-M},
      month = {June},
      doi = {https://doi.org/10.64388/IREV9I12-1718998}
  }